Skip to main content

Johnson & Johnson



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 2%. By the end of trading, Johnson & Johnson rose 62 cents (0.9%) to $67.56 on average volume. Throughout the day, 17.5 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 15.2 million shares. The stock ranged in a price between $67.22-$67.70 after having opened the day at $67.43 as compared to the previous trading day's close of $66.94. Other companies within the Drugs industry that increased today were:

Prima Biomed Ltd. ADR



), up 43.4%,

Ampio Pharmaceuticals



), up 28.9%,

K-V Pharmaceutical Company



), up 21.7%, and

TheStreet Recommends

K-V Pharmaceutical Company



), up 14.9%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. Johnson & Johnson has a market cap of $183.57 billion and is part of the

health care

sector. The company has a P/E ratio of 18.3, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 2.1% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and eight rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a


. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front,

Anthera Pharmaceuticals



), down 16.1%,

Aoxing Pharmaceutical Company



), down 11.5%,




), down 11.1%, and

Supernus Pharmaceuticals



), down 9.1%, were all losers within the drugs industry with

Arena Pharmaceuticals



) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech